Johnson & Johnson (JNJ) Accounts Payables (2009 - 2026)
Johnson & Johnson (JNJ) posted Accounts Payables of $9.2 billion for Q2 2026, down 11.83% sequentially from $10.5 billion in Q1 2026, and down 2.55% YoY from $9.5 billion in Q2 2025.
Johnson & Johnson (JNJ) Accounts Payables (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Accounts Payables for 18 years, with the latest figure at $9.2 billion in Q2 2026.
- Quarterly Accounts Payables fell 2.55% year-over-year to $9.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.2 billion (down 2.55% YoY) and the FY2025 annual result came in at $12.0 billion, up 16.29% from the prior year.
- Accounts Payables declined to $9.2 billion in Q2 2026 per JNJ's latest filing, from $10.5 billion in the prior quarter.
- Over five years, Accounts Payables peaked at $12.0 billion in Q4 2025 and troughed at $8.2 billion in Q1 2024.
- A 5-year average of $9.7 billion and a median of $9.6 billion in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2025: Accounts Payables decreased 17.71% in 2023, then rose 16.77% in 2025.
- Over 5 years, Accounts Payables stood at $10.2 billion in 2022, then slipped by 5.13% to $9.6 billion in 2023, then gained by 7.05% to $10.3 billion in 2024, then climbed by 16.29% to $12.0 billion in 2025, then fell by 23.08% to $9.2 billion in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $9.2 billion, $10.5 billion, and $12.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.22 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3.83 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.58 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -19.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 9.22 Bn |
| Mar 29, 2026 | 10.46 Bn |
| Dec 28, 2025 | 11.99 Bn |
| Sep 28, 2025 | 9.63 Bn |
| Jun 29, 2025 | 9.46 Bn |
| Mar 30, 2025 | 9.55 Bn |
| Dec 29, 2024 | 10.31 Bn |
| Sep 29, 2024 | 8.95 Bn |
| Jun 30, 2024 | 8.85 Bn |
| Mar 31, 2024 | 8.17 Bn |
| Dec 31, 2023 | 9.63 Bn |
| Oct 1, 2023 | 8.36 Bn |
| Jul 2, 2023 | 10.44 Bn |
| Apr 2, 2023 | 9.91 Bn |
| Jan 1, 2023 | 9.89 Bn |
| Oct 2, 2022 | 10.15 Bn |
| Jul 3, 2022 | 9.77 Bn |
| Apr 3, 2022 | 9.31 Bn |
| Jan 2, 2022 | 11.06 Bn |
| Oct 3, 2021 | 8.96 Bn |